Cutaneous squamous cell carcinoma market
Jul 04, 2019
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline
EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
